Welcome!

News Feed Item

Orphan Diseases Partnering Terms and Agreements

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Orphan Diseases Partnering Terms and Agreements

https://www.reportbuyer.com/product/2043441/Orphan-Diseases-Partnering-Terms-and-Agreements.html

The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in orphan diseases partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Orphan diseases partnering contract documents
Top orphan diseases deals by value

The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter orphan diseases partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan diseases technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 90 links to online copies of actual orphan diseases deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of orphan diseases dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in orphan diseases dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading orphan diseases deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech, most active bigpharma/bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapters 4 and 5 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of orphan diseases deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides comprehensive access to all orphan diseases deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive directory of all orphan diseases partnering deals by specific therapeutic indication announced since 2009. The chapter is organized by specific orphan diseases therapeutic indication. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all orphan diseases partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in orphan diseases partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of orphan diseases technologies and products.

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in orphan diseases dealmaking

2.1. Introduction
2.2. Orphan diseases partnering over the years
2.3. Big pharma orphan diseases dealmaking activity
2.4. Big biotech orphan diseases dealmaking activity
2.5. Most active in orphan diseases partnering
2.6. Orphan diseases partnering by deal type
2.7. Orphan diseases partnering by industry sector
2.8. Orphan diseases partnering by stage of development
2.9. Orphan diseases partnering by technology type
2.10. Average deal terms for orphan diseases
2.10.1 Orphan diseases headline values
2.10.2 Orphan diseases upfront payments
2.10.3 Orphan diseases milestone payments
2.10.4 Orphan diseases royalty rates

Chapter 3 - Leading orphan diseases deals

3.1. Introduction
3.2. Top orphan diseases deals by value

Chapter 4 - Big pharma orphan diseases deals

4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma orphan diseases partnering company profiles
Dainippon Sumitomo
Galderma
GlaxoSmithKline
Grifols
Kyowa Hakko Kirin
Mitsubishi Tanabe
Novartis
Pfizer
Sanofi
Shire
Shire Human Genetic Therapies
Takeda
Teva

Chapter 5 - Big biotech orphan diseases deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech orphan diseases partnering company profiles
Acorda Therapeutics
Actelion
BioMarin Pharmaceuticals
Grifols
Ipsen
Isis Pharmaceuticals
Swedish Orphan Biovitrum
ViroPharma

Chapter 6 - Orphan diseases partnering contracts directory

6.1. Introduction

6.2. Company A-Z

Aradigm
Arbios Systems
BioMarin Pharmaceutical
Catalyst Pharmaceutical Partners
Cell Therapeutics
Chiesi Farmaceutici
Chroma Therapeutics
Edison Pharmaceuticals
EpiCept
Galderma
GlaxoSmithKline
GlycoMimetics
Grifols
Halozyme Therapeutics
HepaLife
Hyperion Therapeutics
Ikaria
Intellect Neurosciences
Isis Pharmaceuticals
Kyowa Hakko Kirin
Meda
NovaBay Pharmaceuticals
Orphan Therapeutics
Penwest Pharmaceuticals
Pfizer
S*Bio
Saint Louis University
Ucyclyd Pharma
Ultragenyx Pharmaceuticals
UniQure
Viropharma

6.3. By deal type

Asset purchase
Co-development
Collaborative R&D
Co-market
Development
Equity purchase
Licensing
Marketing
Option
Settlement
Supply

6.4. By stage of development

Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory

6.5. By technology type

Assays
Biological compounds
Biomaterials
Cell culture
Enabling technology
Gene therapy
Implant
Oligonucleotide
Peptides
RNA therapeutics
Screening
Small molecules
Stem cells

Chapter 7 - Orphan diseases dealmaking by therapeutic target

7.1. Introduction
7.2. Deals by therapeutic target
Orphan diseases

Appendices

Appendix 1 - Directory of orphan diseases deals by company A-Z 2009- Jan 2014
Appendix 2 - Directory of orphan diseases deals by deal type 2009- Jan 2014
Appendix 3 - Directory of orphan diseases deals by stage of development 2009-Jan 2014
Appendix 4 - Directory of orphan diseases deals by technology type 2009- Jan 2014
Appendix 5 - Partnering resource center

Online partnering
Partnering events
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Therapy Reports

Table of figures

Figure 1: Orphan diseases partnering since 2009
Figure 2: Big pharma - top 50 - Orphan diseases deals 2009 to 2014
Figure 3: Big pharma orphan diseases deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - Orphan diseases deals 2009 to Jan 2014
Figure 5: Big biotech orphan diseases deal frequency - 2009 to 2014
Figure 6: Active orphan diseases dealmaking activity- 2009 to 2014
Figure 7: Orphan diseases partnering by deal type since 2009
Figure 8: Orphan diseases partnering by industry sector since 2009
Figure 9: Orphan diseases partnering by stage of development since 2009
Figure 10: Orphan diseases partnering by technology type since 2009
Figure 11: Orphan diseases deals with a headline value
Figure 12: Orphan diseases deal headline value distribution, US$million - discovery stage
Figure 13: Orphan diseases deal headline value distribution, US$million - preclinical stage
Figure 14: Orphan diseases deal headline value distribution, US$million - phase I stage
Figure 15: Orphan diseases deal headline value distribution, US$million - phase II stage
Figure 16: Orphan diseases deal headline value distribution, US$million - phase III stage
Figure 17: Orphan diseases deal headline value distribution, US$million - regulatory stage
Figure 18: Orphan diseases deal headline value distribution, US$million - marketed stage
Figure 19: Summary median headline value by stage of development, 2009-2014
Figure 20 Orphan diseases deals with upfront payment values
Figure 21: Orphan diseases deal upfront payment distribution, US$million - discovery stage
Figure 22: Orphan diseases deal upfront payment distribution, US$million - preclinical stage
Figure 23: Orphan diseases deal upfront payment distribution, US$million - phase I stage
Figure 24: Orphan diseases deal upfront payment distribution, US$million - phase II stage
Figure 25: Orphan diseases deal upfront payment distribution, US$million - phase III stage
Figure 26: Orphan diseases deal upfront payment distribution, US$million - regulatory stage
Figure 27: Orphan diseases deal upfront payment distribution, US$million - marketed stage
Figure 28: Summary median upfront payments by stage of development, 2009-2014
Figure 29: Orphan diseases deals with milestone payments
Figure 30: Orphan diseases deal milestone distribution, US$million - discovery stage
Figure 31: Orphan diseases deal milestone distribution, US$million - preclinical stage
Figure 32: Orphan diseases deal milestone distribution, US$million - phase I stage
Figure 33: Orphan diseases deal milestone distribution, US$million - phase II stage
Figure 34: Orphan diseases deal milestone distribution, US$million - phase III stage
Figure 35: Orphan diseases deal milestone distribution, US$million - regulatory stage
Figure 36: Orphan diseases deal milestone distribution, US$million - marketed stage
Figure 37: Orphan diseases deals with royalty rates, %
Figure 38: Orphan diseases deal royalty rate distribution, US$million - discovery stage
Figure 39: Orphan diseases deal royalty rate distribution, US$million - preclinical stage
Figure 40: Orphan diseases deal royalty rate distribution, US$million - phase I stage
Figure 41: Orphan diseases deal royalty rate distribution, US$million - phase II stage
Figure 42: Orphan diseases deal royalty rate distribution, US$million - phase III stage
Figure 43: Orphan diseases deal royalty rate distribution, US$million - regulatory stage
Figure 44: Orphan diseases deal royalty rate distribution, US$million - marketed stage
Figure 45: Summary median royalty rate by stage of development, 2009-2014
Figure 46: Top orphan diseases deals by value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events

Read the full report:
Orphan Diseases Partnering Terms and Agreements

https://www.reportbuyer.com/product/2043441/Orphan-Diseases-Partnering-Terms-and-Agreements.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that FalconStor Software® Inc., a 15-year innovator of software-defined storage solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. FalconStor Software®, Inc. (NASDAQ: FALC) is a leading software-defined storage company offering a converged, hardware-agnostic, software-defined storage and data services platform. Its flagship solution FreeStor®, utilizes a horizonta...
With an estimated 50 billion devices connected to the Internet by 2020, several industries will begin to expand their capabilities for retaining end point data at the edge to better utilize the range of data types and sheer volume of M2M data generated by the Internet of Things. In his session at @ThingsExpo, Don DeLoach, CEO and President of Infobright, will discuss the infrastructures businesses will need to implement to handle this explosion of data by providing specific use cases for filte...
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies adopt disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advanced analytics, and DevO...
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Avere delivers a more modern architectural approach to storage that doesn’t require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbuilding of data centers ...
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management...
SYS-CON Events announced today that Column Technologies will exhibit at SYS-CON's @DevOpsSummit at Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Established in 1998, Column Technologies is a global technology solutions provider with over 400 employees, headquartered in the United States with offices in Canada, India, and the United Kingdom. Column Technologies provides “Best of Breed” technology solutions that automate the key DevOps principal...
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 ad...
The Quantified Economy represents the total global addressable market (TAM) for IoT that, according to a recent IDC report, will grow to an unprecedented $1.3 trillion by 2019. With this the third wave of the Internet-global proliferation of connected devices, appliances and sensors is poised to take off in 2016. In his session at @ThingsExpo, David McLauchlan, CEO and co-founder of Buddy Platform, will discuss how the ability to access and analyze the massive volume of streaming data from mil...
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
When building large, cloud-based applications that operate at a high scale, it’s important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. “Fly two mistakes high” is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Lee...
In most cases, it is convenient to have some human interaction with a web (micro-)service, no matter how small it is. A traditional approach would be to create an HTTP interface, where user requests will be dispatched and HTML/CSS pages must be served. This approach is indeed very traditional for a web site, but not really convenient for a web service, which is not intended to be good looking, 24x7 up and running and UX-optimized. Instead, talking to a web service in a chat-bot mode would be muc...
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
WebSocket is effectively a persistent and fat pipe that is compatible with a standard web infrastructure; a "TCP for the Web." If you think of WebSocket in this light, there are other more hugely interesting applications of WebSocket than just simply sending data to a browser. In his session at 18th Cloud Expo, Frank Greco, Director of Technology for Kaazing Corporation, will compare other modern web connectivity methods such as HTTP/2, HTTP Streaming, Server-Sent Events and new W3C event APIs ...
SYS-CON Events announced today that AppNeta, the leader in performance insight for business-critical web applications, will exhibit and present at SYS-CON's @DevOpsSummit at Cloud Expo New York, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. AppNeta is the only application performance monitoring (APM) company to provide solutions for all applications – applications you develop internally, business-critical SaaS applications you use and the networks that deli...